Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia ... was a key piece of Bristol’s acquisition of Karuna. US regulators approved Cobenfy in September, becoming the first new ...

The drug comes from Bristol Myers Squibb's whopping $14 billion acquisition of biotech company Karuna Therapeutics at the end of 2023. But the drug's roots are in treating Alzheimer's.

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

Amsterdam, the Netherlands, 28 January 2025 - Freya Pharma Solutions, [Freya Pharma, or the Company], a pharmaceutical ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Dear reader, China’s biotechnology sector has rapidly emerged as one of the fastest-growing industries, with Chinese players ...

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...